Ovarian cancer: current approaches to classification, diagnostics, staging and differential management of patients

Cover Page


Cite item

Full Text

Abstract

Purpose of this study: systematic analysis of the data available in the modern scientific medical literature on contemporary aspects of the diagnosis, staging and differential treatment tactics of patients with epithelial ovarian tumors.

Research method used in this article is the systematic analysis of the medical literature, both domestic and western.

Results. This article attempts to summarize the experience of modern medicine and the world’s leading centers for the fight against ovarian cancer of epithelial origin and offer solutions relevant to everyday clinical practice. Problems of the modern classification of forms of the disease are described in detail; description of instrumental diagnostic methods also is given in thus article; problem of lack of effective proved themselves in clinical practice of screening methods also was disccused; and, thus, current understanding of the disease staging and differential tactics for treatment of patients are given.

Conclusion. One of the most important directions of development of gynecological oncology is a decision the existing problems related to the diagnosis and treatment of ovarian cancer: namely, the development of effective screening programs, improving diagnosis and therapy methods, the development of measures of postoperative management of patients with ovarian cancer, including medical rehabilitation measures.

About the authors

Antonina G Solopova

First Moscow Medical Sechenov University

Author for correspondence.
Email: antoninasolopova@yandex.ru

MD, professor of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine

Russian Federation, Moscow, Russia

Victoria O Bitsadze

First Moscow Medical Sechenov University

Email: gemostasis@mail.ru

MD, professor of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine

Russian Federation, Moscow, Russia

Alina E Solopova

First Moscow Medical Sechenov University

Email: dr.solopova@mail.ru

PhD, assistant professor of Department of Radiology

Russian Federation, Moscow, Russia

Aleksandr D Makatsariya

First Moscow Medical Sechenov University

Email: gemostasis@mail.ru

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive

Russian Federation, Moscow, Russia

Ivan A Rozanov

First Moscow Medical Sechenov University

Email: exelbar@yandex.ru

6th year student of Faculty of Medical and Preventive Medicine

Russian Federation, Moscow, Russia

References

  1. Солопова А.Г., Громова М.А., Табакман Ю.Ю. Рецидивирование пограничных опухолей яичников в зависимости от объема хирургического лечения // Врач. – 2008. – № 1. – С. 62–64. [Solopova AG, Gromova MA, Tabakman JuJu. Recidivirovanie pogranichnyh opuholej jaichnikov v zavisimosti ot ob’ema hirurgicheskogo lechenija. Vrach. 2008;(1):62-4. (In Russ.)]
  2. Аксель Е.М. Статистика злокачественных новообразований женской половой сферы // Онкогинекология. – 2012. – Т. 1. – С. 6–15. [Aksel EM. Statistics of malignant tumors of female reproductive system. Onkoginekologija. 2012;1:6-15. (In Russ.)]
  3. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 г. (заболеваемость и смертность). – М., 2013. [Kaprin AD, Starinskiy VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2013g (zabolevaemost’ i smertnost’). Moscow; 2013. (In Russ.)]
  4. Клинические рекомендации по диагностике и лечению больных раком яичников, маточной трубы или первичным раком брюшины / Ассоциация онкологов России. – М., 2014. [Klinicheskie rekomendatsii po diagnostike i lecheniyu bol’nykh rakom yaichnikov, matochnoy truby ili pervichnym rakom bryushiny. Assotsiatsiya onkologov Rossii. Moscow; 2014. (In Russ.)]
  5. Wilkinson N. Pathology of the Ovary, Fallopian Tube and Peritoneum. London: Sprienger-Verlag; 2014.
  6. Ledermann JA, Raja FA, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Onco. 2013;24(Suppl 6):vi24-vi32. doi: 10.1093/annonc/mdt333.
  7. Gusehet SH, et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecologic Oncology. 2014;132:649-53. doi: 10.1016/j.ygyno.2014.01.020.
  8. Prat Jaime and FIGO Committee on Gynecologic Oncology FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87-9. doi: 10.3802/jgo.2015.26.2.87.
  9. Kurman RJ. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J Surg Pathol. 2010;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.
  10. Borley J, Wilhelm-Benartzi C, et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015;122(6):843-9 doi: 10.1111/1471-0528.12992.
  11. Cannistra SA. Cancer of the Ovary. NEJM. 2004;351: 2519-29.
  12. Fujiwara H, Suzuki M, Takeshima N, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015;36(2):1045-53. doi: 10.1007/s13277-014-2738-7.
  13. Spencer JA. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. Eur Radiol. 2010;20:25-35.
  14. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nat Rev Clin Oncol. 2010;7(7):381-93. doi: 10.1038/nrclinonc.2010.47.
  15. Iyer VR, Lee S. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. American Journal of Roentgenology. 2010;194:311-21. doi: 10.2214/AJR.09.3522.
  16. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of Ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. Int J Gynecol Cancer. 2009Feb;19(2):230-6. doi: 10.1111/IGC.0b013e31819c1369.
  17. Forstner R, Meissnitzer MW, Schlattau A, Spencer JA. MRI in ovarian cancer. Imaging Med. 2012;4(1):59-75.
  18. Morgan RJ, Armstrong DK, Alvarez RD, et al. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2. 2015. Available at: http://www.trikobe.org/nccn/guideline/gynecological/english/ovarian.pdf
  19. Wagner U, Harter P, et al. S3-Leitline diagnostik, therapie und nachsorge maligner ovarialtumoren. N.Y.; 2013:103s.
  20. Солопова А.Е., Терновой С.К., Макацария А.Д., Гуров С.Н. Возможности диффузионно-взвешенных последовательностей магнитно-резонансного исследования в оценке эффективности неоадъювантной химиотерапии больных раком яичников // Российский электронный журнал лучевой диагностики. – 2016. – № 4. – C. 68–80. [Solopova AE, Ternovoy SK, Makatsaria AD, Gurov SN. Diffusion weighted magnetic resonance imaging in ovarian cancer neoadjuvant chemotherapy response evaluation. REJR. 2016;(4):68-80. (In Russ.)]
  21. Griffin N, Grant LA, Freeman SJ, et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? Eur Radiol. 2009;19(1):230-5. doi: 10.1007/s00330-008-1121-8.
  22. MacKintosh ML, Rahim R, Rajashanker B, et al. CT scan does not predict optimal debulking in stage III–IV epithelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014;34(5):424-8. doi: 10.3109/ 01443615.2014.899330.
  23. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nat Rev Clin Oncol. 2010;7(7):381-93. doi: 10.1038/nrclinonc.2010.47.
  24. Thomassin-Naggara I, Balvay D, Rockall A, et al. Added value of assessing adnexal masses with advanced MRI techniques. Biomed Res Int. 2015;2015:785206. doi: 10.1155/2015/785206.
  25. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;(11):CD005340. doi: 10.1002/14651858.CD005340.pub3.
  26. Hebel CB, Behrendt FF, Heinzel A, et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Eur J Radiol. 2014;83(3):463-7. doi: 10.1016/j.ejrad.2013.12.006.
  27. Thabet A, Somarouthu B, Oliva E, et al. Image-guided ovarian mass biopsy: efficacy and safety. J Vasc Interv Radiol. 2014;25(12):1922-1927.e1. doi: 10.1016/j.jvir.2014.08.009.
  28. Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. 2015;45(1):49-60. doi: 10.1093/jjco/hyu175.
  29. van Driel CM, de Bock GH, Arts HJ, et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions and outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas. 2015;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009.
  30. Mitchell DG, Javitt MC, Glanc P, et al. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol. 2013;10(11):822-7. doi: 10.1016/j.jacr.2013.07.017.
  31. Katsumata N, Yasuda M, Isonishi S, et al. Long-term follow-up of a randomized trial comparingconventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol. 2012;30(15,suppl.): abstr. 5003.
  32. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-8. doi: 10.1016/S0140-6736(09)61157-0.
  33. Stiekema A, et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic Oncology. 2015;136(3):562-6. doi: 10.1016/j.ygyno.2014.12.037.
  34. Balmana J, Diez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines Ann Oncol 2011;22 (Suppl 6):vi31-4. doi: 10.1093/annonc/mdr373.
  35. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53. doi: 10.1056/NEJMoa0908806.
  36. Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-23. doi: 10.1097/IGC.0b013e3182070f17.
  37. Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001;80:56-61.
  38. Zheng H, Gao YN. Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Chin J Cancer Res. 2012Dec;24(4):304-9. doi: 10.3978/j.issn.1000-9604.2012.09.02.
  39. First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer. Cancer Australia. 2014.
  40. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249-57. doi: 10.1016/S0140-6736(14)62223-6.

Copyright (c) 2017 Solopova A.G., Bitsadze V.O., Solopova A.E., Makatsariya A.D., Rozanov I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies